(Q37769757)

22 August 2017

1 reference

title

Radionuclide and hybrid imaging of recurrent prostate cancer (English)

1 reference

22 August 2017

1 reference

Markus Schwaiger

4

0 references

Michael Souvatzoglou

series ordinal

3

object named as

Michael Souvatzoglou

1 reference

22 August 2017

Ambros J Beer

1

1 reference

22 August 2017

Matthias Eiber

series ordinal

2

1 reference

22 August 2017

Bernd Joachim Krause

series ordinal

5

1 reference

22 August 2017

publication date

6 July 2010

1 reference

Lancet Oncology Commission

22 August 2017

published in

1 reference

22 August 2017

volume

12

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

181-191

1 reference

22 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

1 reference

7 January 2021

2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Positron tomographic assessment of androgen receptors in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Choline transporter as a novel target for molecular imaging of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Fluorocholine PET/CT in patients with prostate cancer: initial experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

18F-Fluoride positron emission tomography and positron emission tomography/computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Indium-111 capromab pendetide in the management of recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Diagnostic bone scanning in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Bone scans with one or two new abnormalities in cancer patients with no known metastases: reliability of interpretation of initial correlative radiographs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Evaluation of combined transmission and emission tomography for classification of skeletal lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

[(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

There are three distinct forms of bombesin. Identification of [Leu13]bombesin, [Phe13]bombesin, and [Ser3,Arg10,Phe13]bombesin in the frog Bombina orientalis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Novel tracers and their development for the imaging of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

The role of alpha(v)beta(3) in prostate cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Prostate and seminal vesicles after irradiation: MR appearance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Localization of Recurrent Prostate Cancer After External Beam Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Role of diffusion-weighted MR imaging in cervical lymphadenopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970103-0

7 January 2021

10.1016/S1470-2045(10)70103-0

Identifiers

DOI

1 reference

22 August 2017

1 reference